Dag Aarsland
Neurology · 2000–2021
A researcher in the Science corpus: 22 papers; trusts 2 researchers and is trusted by 4 researchers here, as inferred from the citation graph.
Subfields
- Neurology — 127 citations into it; #742 of 1,455 by trust here, #68 by citations
- Psychiatry and Mental health — 66 citations into it
- Physiology — 58 citations into it
- Public Health, Environmental and Occupational Health — 6 citations into it
Whom Dag Aarsland trusts overall
Their strongest outbound trust, strongest first, inferred from their citations.
Who trusts Dag Aarsland overall
- S. Sveinbjornsdottir
- Ian G. McKeith
- Michael G. Erkkinen
- Carol Brayne
- Kallol Ray Chaudhuri
- Trevor W. Robbins
- Roger A. Barker
Papers from Dag Aarsland's perspective
Ordered by how strongly the researchers Dag Aarsland trusts endorse each paper. Same corpus, a different order for every researcher.
- Clinical diagnostic criteria for dementia associated with Parkinson's disease (Movement Disorders)
- Risk of dementia in Parkinson’s disease (Neurology)
- What contributes to quality of life in patients with Parkinson's disease? (Journal of Neurology Neurosurgery & Psychiatry)
- The Sydney multicenter study of Parkinson's disease: The inevitability of dementia at 20 years (Movement Disorders)
- Cognitive profile of patients with newly diagnosed Parkinson disease (Neurology)
- MDS clinical diagnostic criteria for Parkinson's disease (Movement Disorders)
- MDS Task Force on Mild Cognitive Impairment in Parkinson’s disease: Critical Review of PD-MCI (Movement Disorders)
- Pimavanserin for patients with Parkinson's disease psychosis: a randomised, placebo-controlled phase 3 trial. (The Lancet)
- Current concepts in mild cognitive impairment. (Archives of Neurology)
- Quantifying the risk of neurodegenerative disease in idiopathic REM sleep behavior disorder (Neurology)
Their papers
- Genome-wide meta-analysis identifies new loci and functional pathways influencing Alzheimer’s disease risk (2019) — 2,006 citations
- Parkinson disease-associated cognitive impairment (2021) — 884 citations
- A genome-wide association study with 1,126,563 individuals identifies new risk loci for Alzheimer’s disease (2021) — 813 citations
- Research criteria for the diagnosis of prodromal dementia with Lewy bodies (2020) — 615 citations
- Diagnosis and management of dementia with Lewy bodies (2017) — 2,290 citations
- Cognitive decline in Parkinson disease (2017) — 954 citations
- Random Forest ensembles for detection and prediction of Alzheimer's disease with a good between-cohort robustness (2014) — 296 citations
- Identifying prodromal Parkinson's disease: Pre‐Motor disorders in Parkinson's disease (2012) — 597 citations
- Diagnostic Criteria for Mild Cognitive Impairment in Parkinson’s Disease: Movement Disorder Society Task Force Guidelines (2012) — 2,505 citations
- MDS Task Force on Mild Cognitive Impairment in Parkinson’s disease: Critical Review of PD-MCI (2011) — 784 citations
- CSF biomarkers and incipient Alzheimer disease in patients with mild cognitive impairment. (2009) — 1,205 citations
- Cognitive impairment in incident, untreated Parkinson disease (2009) — 654 citations
- A systematic review of prevalence studies of depression in Parkinson's disease (2008) — 1,185 citations
- Diagnostic procedures for Parkinson's disease dementia: Recommendations from the movement disorder society task force (2007) — 1,057 citations
- Clinical diagnostic criteria for dementia associated with Parkinson's disease (2007) — 2,957 citations
- Subtypes of mild cognitive impairment in parkinson's disease: Progression to dementia (2006) — 611 citations
- Diagnosis and management of dementia with Lewy bodies (2005) — 3,317 citations
- A systematic review of prevalence studies of dementia in Parkinson's disease (2005) — 1,337 citations
- Rivastigmine for dementia associated with Parkinson's disease. (2004) — 1,162 citations
- Prevalence and characteristics of dementia in Parkinson disease: an 8-year prospective study. (2003) — 1,428 citations